AbbVie Inc. Stock
€177.00
Your prediction
Description AbbVie
AbbVie (ABBV) is a publicly listed pharmaceuticals company headquartered in North Chicago, Illinois, United States. It was established in 2013 as a spinoff from Abbott Laboratories, and currently operates in more than 175 countries worldwide. The company has over 47,000 employees and specializes in research, development, and the commercialization of advanced therapies for a variety of diseases, including immunology, oncology, neuroscience, and virology.
ABBV's flagship product is Humira, which is used to treat a range of autoimmune conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Humira is one of the best-selling prescription drugs globally, generating over $19 billion in 2019.
In addition to Humira, AbbVie also has several other leading drugs in its product portfolio, including Imbruvica, which is used to treat B-cell malignancies like leukemia and lymphoma, and Skyrizi, which is used to treat psoriasis.
ABBV is listed on the New York Stock Exchange (NYSE) under the ticker symbol ABBV, and it is a constituent of the S 500 index. As of 2021, AbbVie has a market capitalization of over $180 billion, making it one of the largest pharmaceutical companies in the world.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Competitors of AbbVie
AbbVie's most important competitors in the pharmaceutical industry are:
1. Johnson Johnson (Symbol: JNJ)
2. Pfizer Inc. (Symbol: PFE)
3. Merck Co., Inc. (Symbol: MRK)
4. Roche Holding AG (Symbol: RHHBY)
5. Sanofi S.A. (Symbol: SNY)
These companies are all large multinational pharmaceutical companies with strong development pipelines, extensive product portfolios, and substantial global reach. They compete with AbbVie in areas such as immunology, oncology, virology, and neuroscience. In addition, they all have a significant presence in emerging markets, where they are competing to capture market share and grow their businesses. Competition in the pharmaceutical industry is intense, and these companies are continually striving to develop new and innovative drugs to stay ahead of their rivals.
Suppliers of AbbVie
AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to patients. The company has a number of important suppliers that help it manufacture the drugs it develops, and ensure the quality and safety of its products. Here are some of the most important suppliers of AbbVie:
1. Raw materials suppliers: AbbVie sources raw materials such as chemical compounds, active pharmaceutical ingredients (APIs), excipients, and packaging materials from a wide range of suppliers around the world. These include large chemical and pharmaceutical companies, as well as smaller suppliers specialized in specific raw materials.
2. Contract manufacturers: AbbVie works with a number of contract manufacturers to produce its drugs on a large scale. These manufacturers operate facilities in the United States, Europe, and Asia, and are selected based on their expertise in specific manufacturing processes and their ability to meet AbbVie's quality standards.
3. Equipment and technology suppliers: AbbVie also relies on a variety of suppliers for equipment and technology used in its manufacturing processes. These include providers of specialized laboratory equipment, automated drug manufacturing systems, and software systems for tracking and documenting production processes.
4. Service providers: AbbVie works with a range of service providers to ensure the quality and safety of its products. These include companies that provide testing and analysis of raw materials and finished products, logistics and transportation services, and certification and compliance services.
Overall, AbbVie's suppliers play a critical role in the company's ability to develop and deliver innovative medicines to patients around the world. The company has established strong relationships with these suppliers to ensure the reliability and consistency of its supply chain, and continues to seek out new partners to support its ongoing research and development efforts.
Financial data and news for AbbVie
sharewise wants to provide you with the best news and tools for AbbVie, so we directly link to the best financial data sources.
Financials
News
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 earnings report. The biopharmaceutical giant reported global net
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
If you have been or are thinking about getting into AbbVie (NYSE: ABBV), there is still time to do so. The AbbVie stock price is in a sustained uptrend
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
AbbVie Inc. (NYSE: ABBV) is trading near an all-time high after the company announced a licensing agreement with Gubra, a Danish company. The agreement
AbbVie Stock: Legal Battle Weighs on Share Price
AbbVie is experiencing a slight downturn in the stock market, with shares currently trading at $209.96, representing a 0.94 percent decline. The pharmaceutical giant's stock dropped by $2.00
If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today
AbbVie (NYSE: ABBV) became a stand-alone, publicly traded company when it split from its former parent, Abbott Laboratories, in 2013. The reason for the split was for each company to generate
3 Stocks Retirees Should Absolutely Love
Priorities change as you enter new seasons of life. That's especially true for your retirement years. And the changing priorities can include what you want from your investments. Income usually
If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today
Think back to 10 years ago. The New England Patriots and their quarterback Tom Brady were accused of underinflating footballs. The Supreme Court affirmed same-sex marriage nationwide. And Apple
3 Unstoppable Stocks to Buy in August
The "it" factor. Some stocks have it. Other stocks don't. But the ones that do can be virtually unstoppable.
Three Motley Fool contributors believe they've found such unstoppable stocks with the
Why AbbVie Stock Flew Higher on Friday
A bellwether stock in the lately rather up-and-down pharmaceutical sector, AbbVie (NYSE: ABBV) finished the trading week in style. The company's shares closed more than 3% higher in price thanks in
Why AbbVie Stock Slumped Today
Shares of AbbVie (NYSE: ABBV) were bouncing along merrily for most of Thursday's trading session, until news of a fresh demand from the White House quashed the rally. Initially, the market was
The 3 Things That Matter for AbbVie Now
It's been a challenging past three years for AbbVie (NYSE: ABBV). The pharmaceutical leader lost U.S. patent exclusivity for its top-selling medicine, Humira, and encountered a significant clinical
3 Dividend Growth Stocks to Buy and Hold
What's better than a great dividend? A great dividend that's growing.
Three Motley Fool contributors think they've found ideal dividend growth stocks to buy and hold -- and all three are healthcare
The Smartest Dividend Stocks to Buy With $300 Right Now
Are dividend stocks only for investors nearing or in retirement? Not at all. Consider that more than half of the S&P 500's (SNPINDEX: ^GSPC) total return over the last 50 years was due to
3 No-Brainer Stocks to Buy in July
Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.
Three Motley Fool contributors think they've found no-brainer stocks to buy
2 Dividend Stocks to Buy for Decades of Passive Income
In 2013, AbbVie (NYSE: ABBV) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (NYSE: ABT). Since then, both have produced strong returns and
Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks
Some stock-trading platforms enable their users to automatically replicate the positions taken by experienced investors or other famous figures. Many investors might prefer to do their own research
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal. A recent study from Ned Davis Research and Hartford
3 Magnificent Stocks That Are Passive Income Machines
Make money without even trying: That's what passive income is all about. But good investment alternatives are required to make this "easy" money.
Three Motley Fool contributors believe they have
Recession Worries? Here's 1 of the Best Dividend Stocks for Turbulent Times
J.P. Morgan stated last month that it believes there is a 60% chance of a recession in 2025 due to trade wars and tariffs. The raging bull market that started at the beginning of 2023 is in
2 High-Yield Dividend Stocks to Buy in May and Hold Forever
When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but the most critical factor to consider is a company's underlying operations.
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market volatility or even economic downturns usually don't affect drugmakers' underlying
Why AbbVie Stock Trounced the Market Today
The positive, post-earnings momentum lifting AbbVie's (NYSE: ABBV) stock price continued on Monday. The veteran healthcare company's shares booked a gain of more than 3% during the trading session
Should Investors Be Worried About Dividend King AbbVie?
Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong